|
|
| (178 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| | __NOTOC__ | | __NOTOC__ |
| | *'''[[Further reading]]''' | | *'''[[Further reading]]''' |
| | + | |
| | + | |
| | *'''[[Unproven ideas]]''' | | *'''[[Unproven ideas]]''' |
| | + | |
| | *'''[[Reviews on covid19 disease]]''' | | *'''[[Reviews on covid19 disease]]''' |
| − | {{tp|p=32335367|t=ä. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response |pdf=|usr=}}
| + | *'''[[Clinical guidelines and advice]]''' |
| | | | |
| − | *'''[[Research tools]]'''
| |
| − | {{tp|p=32142596|t=2020. Machine Learning, COVID?19 (2019?nCoV), and multi?OMICS |pdf=|usr=}}
| |
| − | {{tp|p=32187834|t=2020. ..COVID19: Cytometry and the New Challenge for Global Health |pdf=|usr=}}
| |
| | | | |
| − | *
| |
| − | *'''[[Structure of covid19]]'''
| |
| − | {{tp|p=32311462|t=2020. On the molecular determinants of the SARS-CoV-2 attack |pdf=|usr=}}
| |
| − | {{tp|p=32129843|t=ä. Genomic diversity of SARS-CoV-2 in Coronavirus Disease 2019 patients |pdf=|usr=}}
| |
| − | {{tp|p=32129842|t=ä. A glimpse into the origins of genetic diversity in SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32229288|t=ä. Molecular characterization of SARS-CoV-2 from the first case of COVID-19 in Italy |pdf=|usr=}}
| |
| − | {{tp|p=32341946|t=2020. Chaos game representation dataset of SARS-CoV-2 genome |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Respiration mgmt]]''' |
| | | | |
| | + | *'''[[Diagnosis (Laboratory)]]''' |
| | | | |
| − | *'''[[Target binding and uptake]]'''
| |
| − | {{tp|p=32220422|t=2020. The hosts angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Diagnosis (Lung CT, Sonography)]]''' |
| | + | |
| | + | *'''[[Diagnosis (other modalities)]]''' |
| | + | |
| | + | |
| | + | |
| | + | |
| | + | *'''[[Structure of covid19]]''' |
| | + | |
| | + | |
| | + | *'''[[Target binding and uptake]]''' |
| | *'''[[Cytopathic effects]]''' | | *'''[[Cytopathic effects]]''' |
| | *'''[[Secretion and shedding]]''' | | *'''[[Secretion and shedding]]''' |
| − | {{tp|p=32271376|t=ä. Factors associated with prolonged viral RNA shedding in patients with COVID-19 |pdf=|usr=}}
| + | |
| | + | |
| | | | |
| | *'''[[Innate sensing]]''' | | *'''[[Innate sensing]]''' |
| | + | |
| | *'''[[Immunology]]''' | | *'''[[Immunology]]''' |
| − | {{tp|p=32361250|t=2020. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients |pdf=|usr=}}
| + | |
| | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' | | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' |
| | | | |
| | | | |
| | | | |
| − | *'''[[Microvascular]]''' | + | *'''[[Pathobiology]]''' |
| − | * | + | |
| | + | |
| | + | *'''[[Disease Models]]''' |
| | + | |
| | + | |
| | + | *'''[[Similar diseases and pathomechanisms]]''' |
| | + | |
| | + | |
| | + | |
| | + | |
| | *'''[[Early symptoms]]''' | | *'''[[Early symptoms]]''' |
| | + | |
| | *'''[[Systemic disease, any manifestations]]''' | | *'''[[Systemic disease, any manifestations]]''' |
| − | {{tp|p=32358954|t=ä. Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing |pdf=|usr=}}
| |
| − | {{tp|p=32361747|t=ä. COVID-19, superinfections and antimicrobial development: What can we expect?|pdf=|usr=}}
| |
| − | {{tp|p=32188484|t=2020. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan |pdf=|usr=}}
| |
| − | {{tp|p=32345311|t=2020. Clinical determinants for fatality of 44,672 patients with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32295661|t=ä. Investigating the Determinants of High Case-Fatality Rate for Coronavirus Disease 2019 in Italy |pdf=|usr=}}
| |
| | | | |
| − | *'''[[ARDS]]''' | + | *'''[[Co-Infection]]''' |
| − | {{tp|p=32173725|t=ä. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32161968|t=ä. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias |pdf=|usr=}}
| + | |
| − | {{tp|p=32271373|t=ä. Predictors of refractory Coronavirus disease (COVID-19) pneumonia |pdf=|usr=}}
| + | |
| − | {{tp|p=32375845|t=2020. Acute respiratory failure in COVID-19: is it ?typical? ARDS?|pdf=|usr=}}
| + | |
| − | {{tp|p=32299472|t=2020. COVID-19 pneumonia: ARDS or not?|pdf=|usr=}}
| + | |
| − | {{tp|p=32351860|t=ä. Coronavirus Disease 2019 (COVID-19) Complicated by Acute Respiratory Distress Syndrome: An Internist?s Perspective |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | *'''[[Pulmonary embolism, coagulation]]''' | | *'''[[Pulmonary embolism, coagulation]]''' |
| − | {{tp|p=32334995|t=2020. Concomitant acute aortic thrombosis and pulmonary embolism complicating COVID-19 pneumonia |pdf=|usr=}}
| + | |
| − | {{tp|p=32303472|t=ä. Acute pulmonary embolism in a patient with COVID-19 pneumonia |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | | | |
| | *'''[[Hematology]]''' | | *'''[[Hematology]]''' |
| − | {{tp|p=32178975|t=ä. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis |pdf=|usr=}}
| + | |
| | + | |
| | | | |
| | *'''[[Heart]]''' | | *'''[[Heart]]''' |
| − | {{tp|p=32371557|t=2020. SARS-CoV-2 and myocardial injury: Few answers, many questions |pdf=|usr=}}
| + | |
| − | {{tp|p=32331780|t=ä. COVID-19-related cardiac involvement and potential implications for cardiothoracic imaging |pdf=|usr=}}
| + | |
| − | {{tp|p=32318865|t=2020. Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response |pdf=|usr=}}
| + | |
| − | {{tp|p=32247212|t=2020. Cardiovascular disease and COVID-19 |pdf=|usr=}}
| + | |
| | | | |
| | *'''[[Neurology, ophthalmology, orl]]''' | | *'''[[Neurology, ophthalmology, orl]]''' |
| − | {{tp|p=32283980|t=2020. Clinical Presentation of COVID-19: A Systematic Review Focusing on Upper Airway Symptoms |pdf=|usr=}}
| + | |
| − | {{tp|p=32269598|t=2020. Anosmia and ageusia are emerging as symptoms in patients with COVID-19: What does the current evidence say?|pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | *'''[[Dermatology]]''' | | *'''[[Dermatology]]''' |
| − | *'''[[Gastroenterology, hepatology]]'''
| |
| − | {{tp|p=32347027|t=2020. Acute Hyperglycemic Crises with Coronavirus Disease-19: Case Reports |pdf=|usr=}}
| |
| − | {{tp|p=32347435|t=ä. SARS-CoV-2-Induced Vomiting as Onset Symptom in a Patient with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32285321|t=ä. A Call to Action: Novel Ways that Hepatologists Can Contribute to Patient Care During the COVID-19 Pandemic |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Kidney, urology]]==
| |
| − | {{tp|p=32299479|t=2020. Acute kidney injury in SARS-CoV-2 infected patients |pdf=|usr=}}
| |
| | | | |
| − | *
| |
| − | *'''[[Pathobiology]]'''
| |
| | | | |
| − | *'''[[Disease Models]]''' | + | *'''[[Gastroenterology, hepatology]]''' |
| − | {{tp|p=32215622|t=ä. Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility |pdf=|usr=}}
| + | |
| | | | |
| − | *'''[[Similar diseases and pathomechanisms]]''' | + | *'''[[Kidney, urology]]''' |
| − | *
| + | |
| − | *'''[[Diagnosis (Laboratory)]]'''
| + | |
| − | {{tp|p=32326952|t=2020. SARS-CoV-2 viral load in sputum correlates with risk of COVID-19 progression |pdf=|usr=}}
| + | |
| − | {{tp|p=32313785|t=ä. A Review of Salivary Diagnostics and Its Potential Implication in Detection of Covid-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32295707|t=ä. Fast and simple high-throughput testing of COVID 19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32197339|t=2020. Point-of-Care RNA-Based Diagnostic Device for COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32260471|t=2020. In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends |pdf=|usr=}}
| + | |
| − | {{tp|p=32316113|t=2020. Combining Point-of-Care Diagnostics and Internet of Medical Things (IoMT) to Combat the COVID-19 Pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32244841|t=2020. Blockchain and Artificial Intelligence Technology for Novel Coronavirus Disease-19 Self-Testing |pdf=|usr=}}
| + | |
| | | | |
| | + | *'''[[The morbid survivor]]''' |
| | | | |
| | + | *'''[[Risk and special populations]]''' |
| | | | |
| | | | |
| | | | |
| | + | *'''[[Case reports]]''' |
| | | | |
| − | *'''[[Diagnosis (Lung CT, Sonography)]]'''
| |
| − | {{tp|p=32362428|t=2020. Lessons learned from chest CT in COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32291197|t=2020. COVID-19 pneumonia: A review of typical CT findings and differential diagnosis |pdf=|usr=}}
| |
| − | {{tp|p=32352916|t=2020. "Reversed halo sign" on 3D CT in COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32352917|t=2020. Radiological approach to COVID-19 pneumonia with an emphasis on chest CT |pdf=|usr=}}
| |
| − | {{tp|p=32352918|t=2020. Targeted early chest CT in COVID-19 outbreaks as diagnostic tool for containment of the pandemic- A multinational opinion |pdf=|usr=}}
| |
| − | {{tp|p=32352920|t=2020. MRI appearance of COVID-19 infection |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| − | *'''[[Diagnosis (other modalities)]]'''
| |
| − | {{tp|p=32276598|t=2020. Using echocardiography to guide the treatment of novel coronavirus pneumonia |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Clinical guidelines and advice]]'''
| |
| − | {{tp|p=32360077|t=ä. Estimating severe and critical illness in children with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32311646|t=ä. COVID-19 admissions calculators: General population and paediatric cohort |pdf=|usr=}}
| |
| − | {{tp|p=32344199|t=2020. Sedating ventilated COVID-19 patients with inhalational anesthetic drugs |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Respiration mgmt]]'''
| |
| − | {{tp|p=32371555|t=2020. Utility of extracorporeal membrane oxygenation in COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32357995|t=2020. Tracheal intubation in patients with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32326959|t=2020. High-flow nasal cannula may be no safer than non-invasive positive pressure ventilation for COVID-19 patients |pdf=|usr=}}
| |
| − | {{tp|p=C7156900|t=2020. Prognosis when using extracorporeal membrane oxygenation (ECMO) for critically ill COVID-19 patients in China: a retrospective case series |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Case series]]''' |
| | | | |
| − | *'''[[Risk and special populations]]'''
| |
| − | {{tp|p=32300516|t=ä. Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times |pdf=|usr=}}
| |
| − | {{tp|p=32247213|t=2020. Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infectionwith reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc) |pdf=|usr=}}
| |
| − | {{tp|p=32298981|t=2020. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations |pdf=|usr=}}
| |
| − | {{tp|p=32283499|t=2020. Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers |pdf=|usr=}}
| |
| − | {{tp|p=32334395|t=ä. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia ? A systematic review, meta-analysis, and meta-regression? |pdf=|usr=}}
| |
| − | {{tp|p=32228738|t=ä. Mortality Rate of Infection With COVID-19 in Korea From the Perspective of Underlying Disease |pdf=|usr=}}
| |
| − | {{tp|p=32213760|t=2020. Facts and reflections on COVID-19 and anti-hypertensives drugs |pdf=|usr=}}
| |
| − | {{tp|p=32303915|t=ä. Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)?|pdf=|usr=}}
| |
| − | {{tp|p=C7143201|t=ä. Preventive measures and management of COVID-19 in pregnancy |pdf=|usr=}}
| |
| − | {{tp|p=32323279|t=2020. Renin-Angiotensin-System (RAS) und COVID-19 - Zur Verordnung von RAS-Blockern |pdf=|usr=}}
| |
| − | {{tp|p=32256706|t=2020. COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?|pdf=|usr=}}
| |
| − | {{tp|p=32256705|t=2020. Associations between immune-suppressive and stimulating drugs and novel COVID-19?a systematic review of current evidence |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Case reports]]''' | + | *'''[[Registries]]''' |
| − | {{tp|p=32241316|t=ä. Case Report on Early Diagnosis of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32343659|t=2020. A Moderate Case of COVID-19 Viral Pneumonia During the SARS-CoV-2 Pandemic |pdf=|usr=}}
| + | |
| | | | |
| − | *'''[[Case series]]'''
| |
| − | {{tp|p=32337324|t=2020. The Data set for Patient Information Based Algorithm to Predict Mortality Cause by COVID-19 |pdf=|usr=}}
| |
| | | | |
| | *'''[[Trials]]''' | | *'''[[Trials]]''' |
| | + | |
| | *'''[[Candidate Compounds Covid19]]''' | | *'''[[Candidate Compounds Covid19]]''' |
| − | {{tp|p=32337328|t=2020. Coronaviruses: A patent dataset report for research and development (R&D) analysis |pdf=|usr=}}
| |
| − | {{tp|p=32247211|t=2020. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries |pdf=|usr=}}
| |
| − | {{tp|p=32335366|t=2020. Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis |pdf=|usr=}}
| |
| − | {{tp|p=32333972|t=ä. Letter to the Editor in response to the article ?COVID-19 and diabetes: Can DPP4 inhibition play a role?? |pdf=|usr=}}
| |
| − | {{tp|p=32333966|t=2020. COVID-19 and diabetes: Is this association driven by the DPP4 receptor? Potential clinical and therapeutic implications |pdf=|usr=}}
| |
| − | {{tp|p=32333969|t=ä. Response to COVID -19 and Diabetes: Can DPP4 Inhibition Play a Role? ? GLP-1 Might Play One Too |pdf=|usr=}}
| |
| − | {{tp|p=32283128|t=ä. Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?|pdf=|usr=}} ''on ace2 via adam17, nfkb via dpp4''
| |
| − | {{tp|p=32309622|t=ä. Emerging Therapeutic Strategies for COVID-19 patients |pdf=|usr=}}
| |
| − | {{tp|p=32336723|t=2020. Treatment of SARS-CoV-2: How far have we reached?|pdf=|usr=}}
| |
| − | {{tp|p=32321878|t=2020. Is GSK3beta a molecular target of chloroquine treatment against COVID-19?|pdf=|usr=}}
| |
| − | {{tp|p=32378648|t=2020. Rapid review for the anti-coronavirus effect of remdesivir |pdf=|usr=}}
| |
| − | {{tp|p=32378647|t=2020. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?|pdf=|usr=}}
| |
| − | {{tp|p=32147628|t=2020. Discovering drugs to treat coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32371138|t=ä. Chiral switches of chloroquine and hydroxychloroquine: potential drugs to treat COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32198066|t=ä. Advance of promising targets and agents against COVID-19 in China |pdf=|usr=}}
| |
| − | {{tp|p=32325124|t=ä. Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals |pdf=|usr=}}
| |
| − | {{tp|p=32320852|t=ä. Deja vu: Stimulating open drug discovery for SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32304645|t=ä. Boosting the arsenal against COVID-19 through computational drug repurposing |pdf=|usr=}}
| |
| − | {{tp|p=32266694|t=ä. Chloroquine for COVID-19 Infection |pdf=|usr=}}
| |
| − | {{tp|p=32373183|t=2020. Chloroquine and hydroxychloroquine in the context of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32343658|t=2020. Medication for COVID-19-an Overview of Approaches Currently Under Study |pdf=|usr=}}
| |
| − | {{tp|p=32344202|t=2020. Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development |pdf=|usr=}}
| |
| − | {{tp|p=32249203|t=ä. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | *'''[[The morbid survivor]]'''
| |
| − | *'''[[Biophysics of aerosols]]'''
| |
| | *'''[[Other routes of infection]]''' | | *'''[[Other routes of infection]]''' |
| − | {{tp|p=32241022|t=ä. SARS-CoV-2 is not detectable in the vaginal fluid of women with severe COVID-19 infection |pdf=|usr=}}
| + | |
| − | {{tp|p=32297915|t=ä. Comment of the potential risks of sexual and vertical transmission of Covid-19 infection |pdf=|usr=}}
| + | |
| | + | *'''[[Biophysics of aerosols]]''' |
| | + | |
| | + | |
| | | | |
| | | | |
| | *'''[[Passive protective equipment]]''' | | *'''[[Passive protective equipment]]''' |
| − | {{tp|p=32315026|t=ä. Responding to the COVID-19 outbreak in Singapore: Staff Protection and Staff Temperature and Sickness Surveillance Systems |pdf=|usr=}}
| |
| − | {{tp|p=32166318|t=ä. Protecting Health Care Workers during the COVID-19 Coronavirus Outbreak ?Lessons from Taiwan s SARS response |pdf=|usr=}}
| |
| − | {{tp|p=32354653|t=ä. COVID-19 Pandemic: Survey of future use of personal protective equipment in optometric practice |pdf=|usr=}}
| |
| − | {{tp|p=32354631|t=ä. 3D-printed face protective shield in interventional radiology: evaluation of an immediate solution in the era of COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32223776|t=ä. A Randomized Trial of Instructor-Led Training Versus Video Lesson in Training Health Care Providers in Proper Donning and Doffing of Personal Protective Equipment |pdf=|usr=}}
| |
| − | {{tp|p=32352874|t=2020. Nasal Pressure Injuries During the COVID-19 Epidemic |pdf=|usr=}}
| |
| | | | |
| − | *
| + | |
| | + | |
| | *'''[[Running your hospital]]''' | | *'''[[Running your hospital]]''' |
| − | {{tp|p=32172175|t=2020. Clinical considerations for patients with diabetes in times of COVID-19 epidemic |pdf=|usr=}}
| |
| − | {{tp|p=32283497|t=ä. Telemedicine for Diabetes Care in India during COVID19 Pandemic and National Lockdown Period: Guidelines for Physicians |pdf=|usr=}}
| |
| − | {{tp|p=32344370|t=2020. Industry 4 0 technologies and their applications in fighting COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32305399|t=ä. COVID-19 and diabetes management: What should be considered?|pdf=|usr=}}
| |
| − | {{tp|p=32351631|t=ä. The Need for Diabetes Care Customization in the ICU at the Time of SARS-CoV-2 Outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32229433|t=2020. Interventional radiology and COVID-19: evidence-based measures to limit transmission |pdf=|usr=}}
| |
| − | {{tp|p=32229434|t=2020. How imaging should properly be used in COVID-19 outbreak: an Italian experience |pdf=|usr=}}
| |
| − | {{tp|p=32359930|t=2020. COVID-19 pandemic: A stress test for interventional radiology |pdf=|usr=}}
| |
| − | {{tp|p=32360351|t=ä. Interventional oncology at the time of COVID-19 pandemic: problems and solutions |pdf=|usr=}}
| |
| − | {{tp|p=32209526|t=2020. Management strategy of novel coronavirus (COVID-19) pneumonia in the radiology department: a Chinese experience |pdf=|usr=}}
| |
| − | {{tp|p=32352919|t=2020. Imaging and COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32352915|t=2020. Strategies for radiology departments in handling the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32363528|t=ä. Going Viral: Management of IBD in the Era of the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32323071|t=ä. Emergency Endoscopy During the SARS-CoV-2 Pandemic in the North of Italy: Experience from St Orsola University Hospital?Bologna |pdf=|usr=}}
| |
| − | {{tp|p=32338645|t=2020. ISIDOG Recommendations Concerning COVID-19 and Pregnancy |pdf=|usr=}}
| |
| − | {{tp|p=32276846|t=ä. Challenges in paediatric inflammatory bowel diseases in the COVID-19 time |pdf=|usr=}}
| |
| − | {{tp|p=32291167|t=ä. Covid-19 and cancer patients: Choosing wisely is the key |pdf=|usr=}}
| |
| − | {{tp|p=32360134|t=2020. EUS-guided gallbladder drainage during a pandemic crisis - How the COVID-19 outbreak could impact interventional endoscopy |pdf=|usr=}}
| |
| − | {{tp|p=32360133|t=ä. Screening for Active COVID-19 Infection and Immunization Status Prior to Biologic Therapy in IBD Patients at the Time of the Pandemic Outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32322892|t=ä. Esophageal oncologic surgery in SARS-CoV-2 (COVID-19) emergency |pdf=|usr=}}
| |
| − | {{tp|p=32207676|t=ä. COVID-19 Epidemic in the Middle Province of Northern Italy: Impact, Logistics, and Strategy in the First Line Hospital |pdf=|usr=}}
| |
| − | {{tp|p=32216865|t=ä. Translating COVID-19 Pandemic Surge Theory to Practice in the Emergency Department: How to Expand Structure |pdf=|usr=}}
| |
| − | {{tp|p=32317038|t=ä. Coronavirus Disease 2019 Pandemic: Health System and Community Response to a Text Message (Text4Hope) Program Supporting Mental Health in Alberta |pdf=|usr=}}
| |
| − | {{tp|p=32295659|t=ä. Drawing on Israel?s Experience Organizing Volunteers to Operationalize Drive-Through Coronavirus Testing Centers |pdf=|usr=}}
| |
| − | {{tp|p=32295658|t=ä. Shelter Hospital: Glimmers of Hope in Treating Coronavirus 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32234108|t=ä. How to Surge to Face the SARS-CoV-2 Outbreak: Lessons Learned From Lombardy, Italy |pdf=|usr=}}
| |
| − | {{tp|p=32344439|t=2020. COVID-19-Versorgung - Strategien der Taskforce Coronavirus und Erfahrungen von den ersten 115 Fallen am Universitatsklinikum Freiburg |pdf=|usr=}}
| |
| − | {{tp|p=32236913|t=2020. Rechtsfragen der Ressourcenzuteilung in der COVID-19-Pandemie - Zwischen Utilitarismus und Lebenswertindifferenz |pdf=|usr=}}
| |
| − | {{tp|p=32347112|t=2020. The Effects of the COVID-19/SARS-CoV-2 Pandemic Outbreak on Otolaryngology Activity in Italy |pdf=|usr=}}
| |
| − | {{tp|p=32360075|t=ä. COVID-19 admissions calculators - revisited |pdf=|usr=}}
| |
| − | {{tp|p=32368252|t=2020. Neoadjuvant endocrine therapy for luminal breast cancer treatment: a first-choice alternative in times of crisis such as the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32346393|t=2020. COVID-19 and its ramifications for cancer patients in low-resource settings: Ghana as a case study |pdf=|usr=}}
| |
| − | {{tp|p=32269597|t=2020. Upheaval in cancer care during the COVID-19 outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32346394|t=2020. Additional challenges faced by cancer patients in Gaza due to COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32346392|t=2020. Cancer care in the time of COVID-19?a perspective from Pakistan |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Mental aspects of health professionals]]''' | | *'''[[Mental aspects of health professionals]]''' |
| − | {{tp|p=32248083|t=2020. Doctors and healthcare workers at frontline of COVID 19 epidemic: Admiration, a pat on the back, and need for extreme caution |pdf=|usr=}}
| |
| − | {{tp|p=32229646|t=2020. Staff Mental Health Self-Assessment During the COVID-19 Outbreak |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' | | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' |
| − | {{tp|p=32314954|t=ä. COVID-19 Community Stabilization and Sustainability Framework: An Integration of the Maslow Hierarchy of Needs and Social Determinants of Health |pdf=|usr=}}
| + | |
| − | {{tp|p=32274787|t=2020. Psychische Probleme in der Pandemie - Beobachtungen wahrend der COVID-19-Krise |pdf=|usr=}}
| + | |
| | + | |
| | | | |
| | *'''[[Avoiding clinical medicine in other diseases]]''' | | *'''[[Avoiding clinical medicine in other diseases]]''' |
| | + | |
| | + | |
| | + | |
| | *'''[[Occupational medicine, workplace security and status hygienicus]]''' | | *'''[[Occupational medicine, workplace security and status hygienicus]]''' |
| | + | |
| | + | |
| | *'''[[Economic aspects of the status hygienicus]]''' | | *'''[[Economic aspects of the status hygienicus]]''' |
| | + | |
| | + | |
| | *'''[[Educational aspects of the status hygienicus]]''' | | *'''[[Educational aspects of the status hygienicus]]''' |
| − | *
| + | ---- |
| | + | |
| | + | |
| | *'''[[Host, vector, one health, atmospheric aspects]]''' | | *'''[[Host, vector, one health, atmospheric aspects]]''' |
| | + | |
| | *'''[[Origin of Covid19]]''' | | *'''[[Origin of Covid19]]''' |
| | | | |
| − | {{tp|p=32315626|t=2020. Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak |pdf=|usr=}}
| + | *'''[[Epidemiology]]''' |
| | + | |
| | + | |
| | + | |
| | | | |
| | | | |
| | *'''[[Remission, recurrence and persistence]]''' | | *'''[[Remission, recurrence and persistence]]''' |
| | | | |
| − | *'''[[Epidemiology]]'''
| |
| − | {{tp|p=32346568|t=2020. COVID-19 in Italy: Dataset of the Italian Civil Protection Department |pdf=|usr=}}
| |
| − | {{tp|p=32181302|t=2020. Application of the ARIMA model on the COVID-2019 epidemic dataset |pdf=|usr=}}
| |
| − | {{tp|p=32347022|t=2020. The Outbreak of COVID-19 and Diabetes in Korea: ?We Will Find a Way as We Have Always Done? |pdf=|usr=}}
| |
| − | {{tp|p=32298982|t=2020. Linear Regression Analysis to predict the number of deaths in India due to SARS-CoV-2 at 6 weeks from day 0 (100 cases - March 14th 2020) |pdf=|usr=}}
| |
| − | {{tp|p=32209502|t=2020. Novel coronavirus SARS-CoV-2: familial spread resulting in COVID-19 pneumonia in a pediatric patient |pdf=|usr=}}
| |
| − | {{tp|p=32228732|t=ä. Epidemiological Characteristics on the Clustering Nature of COVID-19 in Qingdao City, 2020: A Descriptive Analysis |pdf=|usr=}}
| |
| − | {{tp|p=32223774|t=ä. Roadblocks to Infection Prevention Efforts in Health Care: SARS-CoV-2/COVID-19 Response |pdf=|usr=}}
| |
| − | {{tp|p=32207674|t=ä. Chronology of COVID-19 Cases on the Diamond Princess Cruise Ship and Ethical Considerations: A Report From Japan |pdf=|usr=}}
| |
| − | {{tp|p=32241325|t=ä. How Is COVID-19 Affecting South Korea? What Is Our Current Strategy?|pdf=|usr=}}
| |
| − | {{tp|p=32317041|t=ä. Management of COVID-19 Outbreak in Argentina: The Beginning |pdf=|usr=}}
| |
| − | {{tp|p=32295652|t=ä. Preparedness is Essential for Western Pacific Islands During the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32285765|t=ä. Public Education and Electronic Awareness of the New Coronavirus (COVID-19): Experiences From Iran |pdf=|usr=}}
| |
| − | {{tp|p=32292266|t=ä. Preventing COVID-19 in low- and middle-income countries |pdf=|usr=}}
| |
| − | {{tp|p=32234107|t=ä. Epidemiologic Features of 135 Patients With Coronavirus Disease (COVID-19) in Tianjin, China |pdf=|usr=}}
| |
| − | {{tp|p=32344440|t=2020. Epidemiologie und Kontrollmassnahmen bei COVID-19 |pdf=|usr=}}
| |
| | | | |
| | + | |
| | + | *'''[[Failure of executive measures]]''' |
| | + | ---- |
| | *'''[[Failure of politics and public health guidance]]''' | | *'''[[Failure of politics and public health guidance]]''' |
| − | {{tp|p=32246996|t=ä. The SARS-CoV-2 epidemic: how the Italian public is being informed |pdf=|usr=}}
| |
| − | {{tp|p=32292239|t=2020. Unpacking the black box: How to promote citizen engagement through government social media during the COVID-19 crisis |pdf=|usr=}}
| |
| − | {{tp|p=32252845|t=ä. Adaptation of the National Plan for the Prevention and Fight Against Pandemic Influenza to the 2020 COVID-19 Epidemic in France |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | *'''[[Failure of executive measures]]'''
| |
| | *'''[[Political abuse of Covid19]]''' | | *'''[[Political abuse of Covid19]]''' |
| − | {{tp|p=C7152572|t=ä. Coronavirus Goes Viral: Quantifying the COVID-19 Misinformation Epidemic on Twitter |pdf=|usr=}}
| + | |
| − | {{tp|p=32241328|t=ä. Limited Early Warnings and Public Attention to Coronavirus Disease 2019 in China, January?February, 2020: A Longitudinal Cohort of Randomly Sampled Weibo Users |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | *'''[[Lost people]]''' | | *'''[[Lost people]]''' |
| | + | |
| | *'''[[Lost civilization]]''' | | *'''[[Lost civilization]]''' |
| | + | |
| | + | ---- |
| | + | |
| | + | |
| | *'''[[History of covid19 exploration]]''' | | *'''[[History of covid19 exploration]]''' |
| − | *'''[[Current state of coviki.org]]'''
| |
| − | *[[PubMed selected papers unsorted to be listed in contents topics]]
| |
| − | *[[coviki state of development]]
| |
| | *'''[[misc.]]''' | | *'''[[misc.]]''' |
| − | {{tp|p=32283498|t=2020. COVID-19: From bench to bed side |pdf=|usr=}}
| |
| − | {{tp|p=32313668|t=2020. COVID-19: A new digital dawn?|pdf=|usr=}}
| |
| − | {{tp|p=32252856|t=ä. Is There a Guarantee That the Crisis of COVID-19 Will not Be Repeated?|pdf=|usr=}}
| |
| − | {{tp|p=32241329|t=ä. Global Health Security Alliance (GloHSA) |pdf=|usr=}}
| |
| − | {{tp|p=32360076|t=ä. Fatherhood during the COVID-19 pandemic: an unexpected turnaround |pdf=|usr=}}
| |
| | | | |
| | + | |
| | + | *'''[[Research tools]]''' |
| | + | |
| | + | |
| | + | |
| | + | |
| | + | {{tp|p=27490990|t=2017. AVCpred: an integrated web server for prediction and design of antiviral compounds |pdf=|usr=}} |
| | + | {{tp|p=25040500|t=2014. Engineering large viral DNA genomes using the CRISPR?Cas9 system |pdf=|usr=}} |
| | + | |
| | + | |
| | + | *'''[[PrePrint scene]]''' |
| | | | |
| | | | |
| | *'''[[from the ads]]''' | | *'''[[from the ads]]''' |
| − | *[http://www.okaybio.com covid19 antibodies, proteins & reagents] | + | |
| − | *[http://www.reactionbiology.com 700 kinsse assays] | + | *'''[[Current state of coviki.org]]''' |
| | + | *'''[[on-topic personal thoughts]]''' |
